Christopher Leamon
Chief Tech/Sci/R&D Officer bij FUSN PHAR
Vermogen: 254 923 $ op 31-03-2024
Profiel
Christopher P.
Leamon is currently the Chief Scientific Officer at Fusion Pharmaceuticals, Inc. He previously worked as the Executive Director-Radioligand Drug Discovery at Novartis Institutes for Biomedical Research, Inc., Principal at Glaxo Wellcome Plc, Vice President-Research at Endocyte, Inc., and Vice President-Discovery Research at Advanced Accelerator Applications USA, Inc. He received his undergraduate degree from Baldwin-Wallace College and his doctorate from Purdue University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-01-2024 | 11 957 ( 0.01% ) | 254 923 $ | 31-03-2024 |
Actieve functies van Christopher Leamon
| Bedrijven | Functie | Begin |
|---|---|---|
| FUSN PHAR | Chief Tech/Sci/R&D Officer | 02-11-2021 |
Eerdere bekende functies van Christopher Leamon
| Bedrijven | Functie | Einde |
|---|---|---|
Advanced Accelerator Applications USA, Inc.
 Advanced Accelerator Applications USA, Inc. Medical SpecialtiesHealth Technology Part of Novartis AG, Advanced Accelerator Applications USA, Inc. develops, produces, and commercializes MNM diagnostic and therapeutic products. The private company is based in New York, NY. | Corporate Officer/Principal | - |
| Glaxo Wellcome Plc | Corporate Officer/Principal | - |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ENDOCYTE, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Christopher Leamon
| Baldwin-Wallace College | Undergraduate Degree |
| Purdue University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FUSN PHAR | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
| Glaxo Wellcome Plc | Health Technology |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Advanced Accelerator Applications USA, Inc.
Advanced Accelerator Applications USA, Inc. Medical SpecialtiesHealth Technology Part of Novartis AG, Advanced Accelerator Applications USA, Inc. develops, produces, and commercializes MNM diagnostic and therapeutic products. The private company is based in New York, NY. | Health Technology |
